<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439345</url>
  </required_header>
  <id_info>
    <org_study_id>CTSULENS1</org_study_id>
    <nct_id>NCT03439345</nct_id>
  </id_info>
  <brief_title>Lowering Events in Non-proliferative Retinopathy in Scotland</brief_title>
  <acronym>LENS</acronym>
  <official_title>A Randomised Placebo-controlled Trial of Fenofibrate to Prevent Progression of Non-proliferative Retinopathy in Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Aberdeen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Scotland Diabetic Retinopathy Screening Collaborative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      LENS is a streamlined multicentre randomized placebo-controlled parallel-group trial&#xD;
      investigating the effect of fenofibrate treatment on the progression of diabetic&#xD;
      retinopathy/maculopathy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LENS is a phase 4 randomised placebo-controlled clinical trial of fenofibrate in participants&#xD;
      with diabetes and observable retinopathy or maculopathy. The trial aims to recruit&#xD;
      approximately 1,060 participants and to treat them for a median duration of at least 4 years.&#xD;
      The main aim of LENS is to investigate the effect of fenofibrate therapy on progression to&#xD;
      clinically significant diabetic retinopathy/maculopathy. The trial will be conducted using a&#xD;
      pragmatic streamlined trial design with the only planned face-to-face visits being an initial&#xD;
      screening visit, followed by a randomisation visit eight weeks later. Contact with&#xD;
      participants thereafter will be by means of regular telephone or computer questionnaire, and&#xD;
      outcome and safety data will also be sought by means of linkage to NHS Scotland registries.&#xD;
      Prior to randomization, eligible participants will enter an active run-in phase of 6 to 10&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 23, 2018</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression to clinically significant diabetic retinopathy/maculopathy</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>The composite of progression to clinically significant diabetic retinopathy/maculopathy or any of retinal laser therapy, vitrectomy or intra-vitreal injection of medication for the treatment of diabetic retinopathy/maculopathy&#xD;
Clinically significant diabetic retinopathy is defined according to NHS Scotland's grading criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Components of the primary outcome (progression to clinically significant diabetic retinopathy/maculopathy; retinal laser therapy; vitrectomy; intra-vitreal injection of medication for treatment of diabetic retinopathy/maculopathy) reported separately</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Number of participants, respectively, in whom the following outcomes occur, reported separately:&#xD;
Number of participants with progression of diabetic retinopathy/maculopathy to clinically significant diabetic retinopathy/maculopathy (based on the NHS Scotland grading scheme)&#xD;
Number of participants requiring retinal laser therapy for diabetic retinopathy/maculopathy (based on patient report and health records)&#xD;
Number of participants requiring vitrectomy for diabetic retinopathy/maculopathy (based on the NHS patient report and health records)&#xD;
Number of participants requiring intra-vitreal injection for diabetic retinopathy/maculopathy (based on the NHS patient report and health records)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any progression of diabetic retinopathy/maculopathy</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Based on the NHS Scotland grading scheme</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Based on measurement of visual acuity at retinal screening visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The development of hard exudates within 1 disc diameter of the macula</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Based on the NHS Scotland grading scheme</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The development of macular oedema</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>The accumulation of macular fluid as determined by optical coherence tomography (OCT) imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual function (according to the VFQ-25 questionnaire)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>According to the VFQ-25 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (according to the EQ-5D questionnaire)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>According to the EQ-5D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cost to the health service</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Health economic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness (incremental cost per QALY gained)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Health economic analysis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in urine albumin:creatinine ratio</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Based on collection of biochemical data</description>
  </other_outcome>
  <other_outcome>
    <measure>The occurrence of major cardiovascular events (myocardial infarction, stroke, coronary and peripheral revascularisation)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Based on patient history and medical records</description>
  </other_outcome>
  <other_outcome>
    <measure>Minor and major non-traumatic lower limb amputation (minor [defined as distal to the ankle] or major [defined as through or proximal to the ankle])</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Based on patient history and medical records</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1151</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Fenofibrate 145 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Name: fenofibrate; Form: tablet; Dosage: 145 mg; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Name: placebo; Form: tablet; Dosage: not applicable; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate 145 mg</intervention_name>
    <description>One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)</description>
    <arm_group_label>Fenofibrate 145 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)</description>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Capable of giving informed consent&#xD;
&#xD;
          2. Diabetes Mellitus (any type except gestational diabetes)&#xD;
&#xD;
          3. Observable diabetic retinopathy/maculopathy (defined based on NHS Scotland grading&#xD;
             criteria as: R1 in both eyes or R2 in one/both eyes at the most recent retinal&#xD;
             screening assessment; or M1 in one/both eyes at any retinal screening assessment in&#xD;
             the 3 years)&#xD;
&#xD;
          4. Willing to either complete electronic questionnaires or conduct telephone interviews&#xD;
             for collection of data once every 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant DR (defined as R3 or R4 or M2 in one or both eyes)&#xD;
&#xD;
          2. History of gallbladder disease (cholecystitis, symptomatic gallstones,&#xD;
             cholecystectomy)&#xD;
&#xD;
          3. History of acute or chronic pancreatitis&#xD;
&#xD;
          4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2X the upper limit&#xD;
             of normal (ULN) according to local NHS laboratory reference range at screening visit&#xD;
&#xD;
          5. ALT or AST &gt;2.5X ULN according to local NHS laboratory reference range at&#xD;
             randomisation visit&#xD;
&#xD;
          6. Creatine kinase (CK) &gt;3X ULN according to local NHS laboratory reference range at&#xD;
             screening visit&#xD;
&#xD;
          7. CK &gt;3X ULN according to local NHS laboratory reference range at randomisation visit&#xD;
&#xD;
          8. Estimated glomerular filtration rate (eGFR) &lt;40mL/min/1.73m2 at screening visit&#xD;
&#xD;
          9. eGFR &lt;30mL/min/1.73m2 at randomisation visit&#xD;
&#xD;
         10. Cirrhosis of any aetiology or any other serious hepatic disease (investigator opinion)&#xD;
&#xD;
         11. Female who is pregnant, breastfeeding, currently trying to become pregnant, or of&#xD;
             child-bearing potential and not practising birth control&#xD;
&#xD;
         12. Ongoing vitamin K antagonist (warfarin, phenindione, acenocoumarol), cyclosporine,&#xD;
             colchicine, ketoprofen, daptomycin, fibrate therapy, or treatment with rosuvastatin&#xD;
             40mg daily&#xD;
&#xD;
         13. Previous myositis, myopathy or rhabdomyolysis of any cause, or diagnosed hereditary&#xD;
             muscle disorder&#xD;
&#xD;
         14. Ongoing renal replacement therapy&#xD;
&#xD;
         15. Any previous organ transplant&#xD;
&#xD;
         16. Previous reported intolerance to any fibrate&#xD;
&#xD;
         17. Medical history that might limit the individual's ability to take trial treatments for&#xD;
             the duration of the study (e.g. severe respiratory disease, history of cancer within&#xD;
             last 5 years other than non-melanoma skin cancer; or recent history of alcohol or&#xD;
             substance misuse)&#xD;
&#xD;
         18. Any other significant disease or disorder which, in the opinion of the Investigator,&#xD;
             may either put the participant at risk because of participation in the trial, or may&#xD;
             influence the result of the trial, or the participant's ability to participate in the&#xD;
             trial&#xD;
&#xD;
         19. LENS participants can participate in other research studies, including clinical&#xD;
             trials. The only exclusions related to co-enrolment will be: if any other study or&#xD;
             trial excludes co-enrolment or if the intervention being investigated in another trial&#xD;
             has the potential to interact with fenofibrate therapy.&#xD;
&#xD;
         20. Not adherent to active run-in treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Preiss, PhD FRCPath</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NHS Grampian</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lanarkshire</name>
      <address>
        <city>Airdrie</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Ayrshire and Arran</name>
      <address>
        <city>Ayr</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Dumfries and Galloway</name>
      <address>
        <city>Dumfries</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Tayside</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Fife</name>
      <address>
        <city>Dunfermline</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lanarkshire</name>
      <address>
        <city>East Kilbride</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Highland</name>
      <address>
        <city>Inverness</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Ayrshire and Arran</name>
      <address>
        <city>Kilmarnock</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Fife</name>
      <address>
        <city>Kirkcaldy</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Forth Valley</name>
      <address>
        <city>Larbert</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Borders</name>
      <address>
        <city>Melrose</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Tayside</name>
      <address>
        <city>Perth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lanarkshire</name>
      <address>
        <city>Wishaw</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.ctsu.ox.ac.uk/lens</url>
    <description>LENS trial website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data generated by LENS will be available on application to bona fide academic researchers via the Richard Doll Centenary Archive, University of Oxford. Applications will be considered in accordance with the RDCA Data Access and Sharing Policy.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_access_criteria>Applications will be considered in accordance with the RDCA Data Access and Sharing Policy.</ipd_access_criteria>
    <ipd_url>https://www.ndph.ox.ac.uk/about/richard-doll-centenary-archive</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

